1 Min Read Systemic Lupus Erythematosus
7 月 28, 2026Core Framework & Diagram Systemic Lupus Erythematosus
7 月 28, 2026Lupus is not a 'skin disease' — it's the immune system launching indiscriminate war against the entire body
—— The butterfly rash is just the tip of the iceberg. The real battlefields are the kidneys, brain, and blood vessels.
I. Why does lupus attack its own DNA?
Lupus's most confusing question is: why does the immune system attack its own DNA? The answer requires starting with 'apoptosis' and 'clearance failure.' Normally, billions of cells undergo programmed death (apoptosis) daily. During apoptosis, DNA and proteins in cell nuclei are 'packaged' into apoptotic bodies, waiting to be rapidly recognized and engulfed by macrophages — not exposed to the immune system. This clearance process runs efficiently in healthy individuals and is one of the key mechanisms preventing autoimmunity.
Lupus patients have an 'apoptotic clearance defect' — apoptotic bodies can't be cleared in time, accumulate in tissue, and undergo 'secondary necrosis,' releasing nuclear materials into the extracellular environment. These nuclear materials are 'danger signals' for plasmacytoid dendritic cells (pDCs), triggering massive secretion of type I interferon (IFN-α/β). Over seventy percent of lupus patients show persistently high type I interferon signal expression in blood — this 'interferon signature' is one of lupus research's most important biomarkers, and is also the treatment target for the newest targeted drug anifrolumab.
Understanding this mechanism also explains why UV radiation is an important lupus trigger: UV directly damages skin cell DNA, accelerates production of apoptotic cells, and increases the 'clearance overload.'
2. Lupus nephritis — the most critical organ involvement to watch
Kidneys are lupus's most common and most dangerous affected organ. Approximately fifty to sixty percent of lupus patients develop renal involvement (lupus nephritis, LN) during their disease course; in Asian populations the proportion exceeds sixty percent. Immune complexes (self-antibody + nuclear antigen combinations) deposit in the glomerular vascular network, activate the complement system, recruit inflammatory cells, trigger glomerular inflammation, and subsequently cause glomerulosclerosis and renal function damage. Untreated lupus nephritis can progress to end-stage renal disease within years, requiring dialysis or kidney transplantation.
Lupus nephritis classification (Types I through VI, per WHO/ISN classification) determines treatment intensity. Types III/IV (diffuse glomerulonephritis) are the most severe, requiring aggressive immune suppression (high-dose steroids + mycophenolate or cyclophosphamide). Type V (membranous nephropathy) has relatively better prognosis. Renal biopsy is the gold standard for classification and treatment guidance.
|
How important is regular urinalysis for lupus patients? Urinary protein quantification and urine sediment analysis are the simplest, most important means of early detection of renal involvement. Every three to six months, even when 'feeling completely normal,' don't skip this test. |
3. Neuropsychiatric lupus — the most easily misdiagnosed battlefield
Neuropsychiatric system involvement (NPSLE) is another severely underestimated lupus battlefield. Approximately twenty to forty percent of lupus patients develop neuropsychiatric manifestations including: headache (especially migraine-like), cognitive impairment (commonly called 'lupus brain fog'), emotional fluctuations and depression, seizures, and stroke. 'Lupus brain fog' is the most common but hardest to quantify NPSLE presentation — patients describe memory decline, difficulty concentrating, word-finding trouble — while routine neurological exams and MRI are often normal. This makes many patients' cognitive symptoms get attributed to 'anxiety' or 'worrying too much,' when in fact this is a real neuroinflammatory process.
Approximately thirty to forty percent of lupus patients are positive for antiphospholipid antibodies (aPL) — these antibodies increase arterial and venous thrombosis risk, elevating stroke risk ten to twenty times above average. Antiphospholipid syndrome (APS) can occur independently of lupus or as part of lupus. aPL-positive lupus patients need long-term low-dose aspirin (usually 100mg daily) as thrombosis prophylaxis; those who've already experienced thrombosis need anticoagulation treatment. This aPL-related thrombosis risk is critical information that must be proactively communicated to doctors before hospitalization or surgery.
4. Lupus and pregnancy — high risk, but not impossible
Pregnancy in lupus during active disease phase carries extremely high risks: miscarriage rates, premature birth rates, and eclampsia risks are significantly elevated; fetal intrauterine growth restriction can affect twenty to thirty percent. But pregnancy during disease remission (six or more continuous months without activity) has dramatically reduced risk: under specialist supervision, most lupus patients can complete relatively safe pregnancies.
This understanding is critically important, because lupus primarily affects women of reproductive age. Many patients give up treatment out of concern about pregnancy, or take the risky step of getting pregnant during active disease — both lead to serious consequences. Anti-Ro/SSA antibody-positive mothers have a one to two percent chance of fetal 'neonatal lupus,' with cardiac conduction block the most serious complication requiring specialized pregnancy monitoring (fetal echocardiogram every one to two weeks from weeks sixteen to twenty-six). Hydroxychloroquine (HCQ) is one of the few lupus drugs usable during pregnancy, with research showing it can reduce pregnancy complications and neonatal lupus incidence — it shouldn't be arbitrarily stopped during pregnancy; quite the opposite, maintaining HCQ during pregnancy has clear benefits.
5. Today's lupus treatment — from symptom control to targeting the disease mechanism
In 2011, belimumab became the first new drug approved by the FDA for lupus in fifty years, targeting BAFF (B cell activating factor). In 2022, anifrolumab (targeting type I interferon receptors) was approved — directly targeting the 'IFN signature,' one of the most mechanistically precise breakthroughs in lupus treatment history, particularly effective for the IFN signature-positive subgroup (over seventy percent of lupus patients).
Today's lupus treatment is tiered: hydroxychloroquine (HCQ) is baseline treatment for all patients; active phases add steroids + immunosuppressants (mycophenolate, azathioprine); biologics for moderate-severe or standard treatment non-responders.
Modern treatment has transformed lupus from 'a disease with significantly shortened life expectancy' to 'a chronic disease with maintainable normal quality of life under standardized treatment.' In the 1970s, lupus patients' five-year survival rate was approximately fifty percent. Today under standardized treatment, ten-year survival exceeds ninety percent — change driven by early diagnosis, standardized treatment, and systematic management of renal, cardiovascular, and other complications.
6. Lupus and mental health: the overlooked battlefield
Lupus's impact on mental health is far deeper than most people realize. Approximately forty to fifty percent of lupus patients report clinically significant depression; approximately thirty percent have anxiety disorder — rates far higher than the general population and higher than most other chronic disease patients. Causes are multilayered: the disease's unpredictability (not knowing when relapse will come), long-term pain and fatigue draining mental resources, corticosteroids' direct effects on mood, social function limitations (too fatigued to participate in social activities), and uncertainty about fertility and the future.
Importantly, lupus-related depression and anxiety aren't 'just psychological problems' — they also have biological foundations. Type I interferon excess itself has direct inflammatory effects on the central nervous system, changing neurotransmitter metabolism. This means controlling disease activity itself (lowering interferon levels, reducing inflammation) is equally effective at improving emotional state. Psychological interventions (cognitive behavioral therapy, supportive psychotherapy) and medical treatment often need to proceed simultaneously — not 'fix the disease first, then address the psychology.'
Frequently Asked Questions